JP2025500438A5 - - Google Patents

Info

Publication number
JP2025500438A5
JP2025500438A5 JP2024538028A JP2024538028A JP2025500438A5 JP 2025500438 A5 JP2025500438 A5 JP 2025500438A5 JP 2024538028 A JP2024538028 A JP 2024538028A JP 2024538028 A JP2024538028 A JP 2024538028A JP 2025500438 A5 JP2025500438 A5 JP 2025500438A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
modified
nucleic acid
nucleoside
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082164 external-priority patent/WO2023122681A2/en
Publication of JP2025500438A publication Critical patent/JP2025500438A/ja
Publication of JP2025500438A5 publication Critical patent/JP2025500438A5/ja
Pending legal-status Critical Current

Links

JP2024538028A 2021-12-22 2022-12-21 Pcdh19発現を低減するための化合物及び方法 Pending JP2025500438A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292829P 2021-12-22 2021-12-22
US63/292,829 2021-12-22
PCT/US2022/082164 WO2023122681A2 (en) 2021-12-22 2022-12-21 Compounds and methods for reducing pcdh19 expression

Publications (2)

Publication Number Publication Date
JP2025500438A JP2025500438A (ja) 2025-01-09
JP2025500438A5 true JP2025500438A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=86903772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538028A Pending JP2025500438A (ja) 2021-12-22 2022-12-21 Pcdh19発現を低減するための化合物及び方法

Country Status (4)

Country Link
US (1) US20250340874A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453216A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500438A (cg-RX-API-DMAC7.html)
WO (1) WO2023122681A2 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US9873723B2 (en) * 2008-01-04 2018-01-23 The University Of Melbourne Diagnostic and therapeutic methods for EFMR (epilepsy and mental retardation limited to females)
CN102388139A (zh) * 2008-11-04 2012-03-21 艾德拉药物股份有限公司 通过反义寡核苷酸来调制Toll样受体5表达
US9567581B2 (en) * 2012-08-07 2017-02-14 The General Hospital Corporation Selective reactivation of genes on the inactive X chromosome

Similar Documents

Publication Publication Date Title
JP7315594B2 (ja) Lrrk2発現を低減するための化合物及び方法
TWI809004B (zh) 用於降低snca表現之化合物及方法
JP2022515193A5 (cg-RX-API-DMAC7.html)
EP3664816A1 (en) Oligonucleotide compositions and methods thereof
JP2022518929A5 (cg-RX-API-DMAC7.html)
JP2022527105A5 (cg-RX-API-DMAC7.html)
JP2023536472A5 (cg-RX-API-DMAC7.html)
JP7446443B2 (ja) Smn2を調節するための化合物及び方法
JP2024504377A5 (cg-RX-API-DMAC7.html)
JP2023536994A5 (cg-RX-API-DMAC7.html)
CN119790152A (zh) 使用unc13a基因转录本的调节剂治疗神经系统疾病
CN119522282A (zh) 具有经修饰的主链化学的剪接转换器反义寡核苷酸
KR20240049349A (ko) Scn1a 발현을 조절하기 위한 화합물 및 방법
JP2023543215A5 (cg-RX-API-DMAC7.html)
JP2023528755A5 (cg-RX-API-DMAC7.html)
JP2023530072A5 (cg-RX-API-DMAC7.html)
AU2021284360A1 (en) Treatment of neurological diseases using modulators of gene transcripts
TW202111123A (zh) 用於減少fus 表現之化合物及方法
JP2024522147A5 (cg-RX-API-DMAC7.html)
JP2023532518A (ja) Plp1を調節するための化合物及び方法
WO2021157730A1 (ja) 核酸医薬とその使用
JP2026506010A (ja) App発現を低減するための化合物及び方法
CN121986163A (zh) 修饰的unc13a寡核苷酸
TW202435898A (zh) 用於調節杭丁頓蛋白表現之對偶基因選擇性化合物及方法
JP2025532127A (ja) Mecp2発現を低減する化合物及び方法